Advertisement

Topics

Alkermes initiates ALKS 5461 NDA for major depressive disorder

10:37 EDT 22 Aug 2017 | CentreWatch

Alkermes announced the initiation of its rolling submission of a New Drug Application (NDA) to the FDA, seeking marketing approval of ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action, for the adjunctive treatment of major depressive disorder (MDD). The company expects to complete the submission of the NDA for this […]

The post Alkermes initiates ALKS 5461 NDA for major depressive disorder appeared first on CenterWatch News Online.

Original Article: Alkermes initiates ALKS 5461 NDA for major depressive disorder

NEXT ARTICLE

More From BioPortfolio on "Alkermes initiates ALKS 5461 NDA for major depressive disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...